The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 million in its initial public offering, Exscientia (EXAI -4.17%) has thrown in the towel and agreed to merge with Recursion Pharmaceuticals (RXRX -5.27%), another AI-driven drug developer.In a nutshell, these b ...

On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, with fractional shares paid in cash.Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% of the combined entity, and Exscientia shareholders will own approximately 26%.Also Read: Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism.“We believe ...

文章核心观点 - 公司将Recursion的生物探索和转化能力与Exscientia的精准化学设计和小分子自动合成能力结合,创建了一个领先的技术驱动的端到端药物发现平台 [1][2] - 结合后的公司将利用生命科学和技术的最新进展,为患者提供更好、更快、更低成本的新型治疗方法 [1][3][4] - 公司拥有丰富的临床管线,未来18个月内预计有约10个临床试验结果 [1][5] - 公司与多家大型制药公司建立了行业领先的合作伙伴关系,未来24个月内可能获得约2亿美元里程碑付款,整个合作期内可能获得超过200亿美元收益(不含版税) [1][6][12] - 公司资产负债表健康,截至2024年第二季度末拥有约8.5亿美元的现金及等价物 [1] - 预计整合后每年可产生超过1亿美元的协同效应 [1][14] 根据目录分别总结 管线 - 结合后的公司拥有多个临床和临床前项目,未来18个月内预计有约10个临床试验结果 [1][5][8] - 公司管线涵盖罕见病、精准肿瘤和传染病等领域,大部分成功项目有可能达到超过10亿美元的年峰值销售 [11] - 两家公司的管线互补,Recursion专注于首创药物,Exscientia专注于最佳在类药物 [11] - 两家公司还有多个研发和发现阶段的管线项目,将从两个平台的互补性中获益 [11] 合作伙伴 - 结合后的公司将拥有与多家大型制药公司(如罗氏-基因泰克、赛诺菲、拜耳和默克)的变革性合作关系,涉及10个肿瘤和免疫学领域的项目 [6][10][12] - 未来24个月内可能获得约2亿美元里程碑付款,整个合作期内可能获得超过200亿美元收益(不含版税) [1][6][12] 技术平台 - 结合后的公司将拥有一个全栈的技术驱动平台,涵盖从患者导向的靶标发现到临床开发的各个环节 [13] - Exscientia的自动化合成能力将使Recursion能够更快更有效地进行命中化合物到先导化合物的优化 [13] - 这些能力将产生多样性化学,有助于实验性地改善生物化学的预测模型 [13]

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeli ...

NEW YORK, June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/exscientia-plc-loss-submission-form/?id=87099&from=4 CLASS PERIOD: March 23, 2022 to Fe ...

LOS ANGELES, June 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period" ...

文章核心观点 - 公司Exscientia p.l.c.的投资者在2022年3月23日至2024年2月12日期间购买公司普通股或期权的投资者可能有权获得赔偿[1][2][3] - 根据诉讼,公司高管存在不当行为,包括与员工存在不当关系、未能适当处理不当行为以及公司的商业行为准则执行不力,这可能给公司带来领导层变动和声誉损害的风险[5] - 当这些信息被披露后,投资者遭受损失[5] 根据相关目录分别进行总结 诉讼信息 - 投资者可以通过Rosen Law Firm提起集体诉讼,并在2024年6月25日之前申请成为首席原告[3] - Rosen Law Firm是一家专注于证券集体诉讼的律师事务所,在此类案件中有丰富的经验和成功案例[4] 加入诉讼的方式 - 投资者可以通过Rosen Law Firm的网站或致电律师获取加入诉讼的信息[3][6][7] - 在集体诉讼获得认证之前,投资者可以自行选择律师代表,也可以选择不采取任何行动[7]

NEW YORK, June 24, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds those who purchased common stock or purchased call options or sold put options, including any common stock purchased or otherwise acquired in connection with the exercise of such options of Exscientia p.l.c. (NASDAQ: EXAI), between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Exscientia se ...

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"). If you suffered a loss on your Exscientia investments or would like to inquire about potentially purs ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c. (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...